FRI0165 Relationship Between Serum Concentrations of Cytokines and Disease Activity in Rheumatoid Arthritis Patients Treated with Tocilizumab

In order to investigate the predictive factors related to clinical efficacy and radiographic progression at 24 weeks by looking at the serum levels of tumor necrosis factor (TNF)-α and interleukin (IL)-6 including baseline characteristics in patients with rheumatoid arthritis (RA) treated with golimumab, serum concentrations of TNF-α and IL-6 were analyzed every 4 weeks up to 24 weeks in 47 patients treated with golimumab. Baseline levels of the Disease Activity Score 28 C-reactive protein (DAS28-CRP) and Simplified Disease Activity Index (SDAI) scores were also assessed. Radiographic progression using the van der Heijde-modified Sharp (vdH-S) score was assessed in 29 patients. Multiple regression analyses related to the DAS28-CRP score and delta total sharp score at 24 weeks was undertaken using the baseline characteristics of patients and serum concentrations of matrix metalloproteinase (MMP)-3, TNF-α, and IL–6. The DAS28-CRP score and SDAI decreased significantly at 4 weeks up to 24 weeks compared with baseline. Serum levels of TNF-α were not changed significantly up to 24 weeks compared with baseline, but those of IL-6 decreased significantly at 4 weeks up to 8 weeks. Multiple regression analyses showed that disease duration and serum levels of MMP-3 were related significantly to the DAS28-CRP score at 24 weeks. Radiographic progression was related significantly to disease duration with regard to joint space narrowing and bone erosion. However, serum levels of TNF-α and IL-6 were not correlated significantly with the DAS28-CRP score and radiographic progression. These data suggest that decreasing serum levels of IL-6 significantly, MMP-3, and disease duration are predictive factors for RA activity in patients taking golimumab.

Download Full-text

Neopterin, soluble adhesion molecules and soluble cytokine receptors correlate with disease activity in rheumatoid arthritis

Pteridines ◽

10.1515/pteridines.2000.11.2.54 ◽

2000 ◽

Vol 11 (2) ◽

pp. 54-59 ◽

Cited By ~ 1

Author(s):

El Nassonov ◽

My Samsonov ◽

Gp Tilz ◽

Ny Chichasova ◽

B Widner ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Disease Activity ◽

Adhesion Molecules ◽

Intercellular Adhesion ◽

Cytokine Receptors ◽

Healthy Controls ◽

Serum Concentrations ◽

Soluble Adhesion Molecules ◽

Intercellular Adhesion Molecules

AbstractSerum concentrations of soluble intercellular adhesion molecules, sICAM-I , sICAM-3 and sP-selectin, of serum soluble cytokine receptors, sIL-2R, and sTNF-R55 and of neopterin were measured by commercially available immunoassays in 35 patients with rheumatoid arthritis (RA). Serum sICAM-I, sICAM-3 and sPselectin were significantly elevated in patients with RA compared with healthy controls. Concentrations of sPselectin and sICAM-3 correlated with disease activity and severity indices. sICAM-3 levels significantly correlated with sTNF-R55 and neopterin. There were significant correlations between neopterin and sIL-2R and between sTNF-R55 and sIL-2R. The measurement of sP-selectin and sICAM-3 levels in patients with RA might become useful for monitoring disease activity.

Download Full-text

Effect of IL-6 Receptor Blockade on Proprotein Convertase Subtilisin/Kexin Type-9 and Cholesterol Efflux Capacity in Rheumatoid Arthritis Patients

Hormone and Metabolic Research ◽

10.1055/a-0833-4627 ◽

2019 ◽

Vol 51 (03) ◽

pp. 200-209 ◽

Cited By ~ 8

Author(s):

Iván Ferraz-Amaro ◽

María Hernández-Hernández ◽

Beatriz Tejera-Segura ◽

Esmeralda Delgado-Frías ◽

María Macía-Díaz ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Physical Activity ◽

Plasma Concentration ◽

Disease Activity ◽

Cholesterol Efflux ◽

Ldl Cholesterol ◽

Serum Concentrations ◽

Cholesterol Efflux Capacity ◽

Hs Crp ◽

One Year

AbstractThe aim of the work was to examine whether abnormalities in the lipid profile that tocilizumab (TCZ), an anti-IL-6 receptor Ab, exerts in rheumatoid arthritis (RA) patients is related to changes in either proprotein convertase subtilisin/kexin-9 (PCSK9) serum concentrations or in serum cholesterol efflux capacity (CEC). TOCRIVAR is a one-year prospective clinical trial that analyzes the influence of TCZ on cardiovascular risk factors. Twenty-seven RA patients receiving TCZ (8 mg/kg IV/q4w) were assessed at baseline and weeks 12, 24, and 52. Disease activity indexes, adiposity composition, physical activity, serum CEC, PCSK9, and lipoproteins serum concentrations were assessed at every visit. Basal high-sensitivity C-reactive protein (hs-CRP) and disease activity were markedly reduced throughout one-year TCZ treatment. While initially total cholesterol and LDL cholesterol increased their plasma concentration, decreasing to basal afterwards, lipoprotein(a) was significantly lower than basal in all visits of the study. CEC increased after 24 week of treatment proportionally to hs-CRP reduction, and remained significantly higher after week 52 [median % change 32 (3–141), p=0.021]. Interestingly, variations in LDL cholesterol basal concentration along the one year of TCZ treatment correlated directly with changes of PCSK9 serum concentration (r=0.37, p=0.003). Basal abdominal adiposity, BMI, and physical activity remained stable during the study. Long-term TCZ-treated RA patients show an increment in CEC inversely proportional to hs-CRP reduction and changes in LDL cholesterol that might be explained, at least in part, by variations in PCSK9 plasma concentration. Overall, TCZ treatment produces a favorable qualitative net effect in terms of atherogenic implication in RA patients.

Download Full-text

Clusterin serum levels are elevated in patients with early rheumatoid arthritis and predict disease activity and treatment response

Scientific Reports ◽

10.1038/s41598-021-90973-2 ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Tereza Kropáčková ◽

Heřman Mann ◽

Olga Růžičková ◽

Olga Šléglová ◽

Lucia Vernerová ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Disease Activity ◽

Treatment Response ◽

Early Rheumatoid Arthritis ◽

Roc Analysis ◽

Predictive Biomarker ◽

Serum Levels ◽

Serum Concentrations ◽

Low Disease Activity ◽

Treatment Naïve

AbstractClusterin (CLU) is a molecular chaperone that participates in a variety of biological processes. Recent studies indicate its possible involvement in the development of bone erosions and autoimmunity. The aim of this study was to investigate its serum concentrations in patients with early rheumatoid arthritis (RA) and to explore their potential relationship with disease activity and treatment response. Serum levels of CLU were measured in 52 patients before and 3 months after the initiation of treatment and in 52 healthy individuals. CLU levels at baseline were significantly increased in patients with early RA compared with healthy subjects (p < 0.0001). After 3 months of treatment, the levels of CLU decreased and reached concentrations comparable to those in controls. Even though there was no relationship between CLU levels and disease activity at baseline, CLU levels positively correlated with disease activity at months 3, 6 and 12 after treatment initiation. Using ROC analysis, lower CLU baseline levels predicted achieving the therapeutic target of low disease activity and remission at months 3, 6 and 12. In summary, we found increased serum concentrations of clusterin in treatment-naïve patients with early rheumatoid arthritis, and we suggest clusterin as a predictive biomarker of disease activity and treatment response.

Download Full-text

Metabolic Profile and Bone Status in Post-Menopausal Women with Rheumatoid Arthritis: A Monocentric Retrospective Survey

Nutrients ◽

10.3390/nu13093168 ◽

2021 ◽

Vol 13 (9) ◽

pp. 3168

Author(s):

Sabrina Paolino ◽

Elvis Hysa ◽

Sabrina Atena Stoian ◽

Emanuele Gotelli ◽

Andrea Casabella ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Insulin Resistance ◽

Disease Activity ◽

Trabecular Bone Score ◽

Bone Microarchitecture ◽

Significant Negative Correlation ◽

Serum Concentrations ◽

Mineral Density ◽

Bone Status ◽

Post Menopausal

Background: Rheumatoid arthritis (RA) and metabolic syndrome (MetS) are chronic conditions that share common inflammatory mechanisms. Both diseases can lead to an impairment of the bone microarchitecture. The aims of our study were to evaluate clinical, metabolic, and bone parameters in RA patients with or without MetS (MetS+, MetS−) and potential correlations between the glico-lipidic profile, RA disease activity, and bone status. Methods: A total of thirty-nine RA female post-menopausal patients were recruited (median age 66.6 ± 10.4, disease duration 3 ± 2.7). Anthropometric data, medical history, and current treatment were recorded along with basal blood tests, bone, and lipid metabolism biomarkers. RA disease activity and insulin resistance were evaluated through standard scores. Quantitative assessment of the bone (bone mineral density—BMD) was performed by dual-energy-X ray absorption (DXA), whereas bone quality was quantified with the trabecular bone score (TBS). Results: No statistically significant differences concerning both BMD and TBS were detected between the MetS+ and MetS− RA patients. However, the MetS+ RA patients exhibited significantly higher disease activity and lower serum 25-hydroxyvitamin D [25(OH)D] concentrations (respectively, p = 0.04 and p = 0.01). In all RA patients, a significant negative correlation emerged between the BMD of the femoral trochanter with plasmatic triglycerides (TG) concentrations (r = −0.38, p = 0.01), whereas the lumbar BMD was positively correlated with the abdominal waist (AW) and fasting glucose (FG) concentrations. On the other hand, the TBS was negatively correlated with insulin concentrations, FG, and RA disease activity (respectively, r = −0.45, p = 0.01, r = −0.40, p = 0.03, r = −0.37, p = 0.04), the last one was further negatively correlated with 25-OHD serum concentrations (r = −0.6, p = 0.0006) and insulin-resistance (r = 0.3, p = 0.04). Conclusions: Bone quantity (BMD) and quality (TBS) do not seem significantly changed among MetS+ and MetS− RA patients; however, among MetS+ patients, both significantly higher disease activity and lower vitamin D serum concentrations were observed. In addition, the significant negative correlations between the alterations of metabolic parameters limited to the TBS in all RA patients might suggest that qualitative bone microarchitecture impairments (TBS) might manifest despite unchanged BMD values.

Download Full-text

Association between vitamin D and fatigue in patients with rheumatoid arthritis: a cross-sectional study

BMJ Open ◽

10.1136/bmjopen-2019-034935 ◽

2020 ◽

Vol 10 (2) ◽

pp. e034935

Author(s):

Lars Petter Jelsness-Jørgensen ◽

Lars Grøvle ◽

Anne Julsrud Haugen

Keyword(s):

Rheumatoid Arthritis ◽

Vitamin D ◽

Psychological Distress ◽

Disease Activity ◽

Cross Sectional Study ◽

Serum Concentrations ◽

Sectional Study ◽

Cross Sectional ◽

Hydroxyvitamin D ◽

Liquid Chromatography Tandem Mass

ObjectivesIn rheumatoid arthritis (RA), fatigue is an important complaint with a significant impact on quality of life. Vitamin D has modulatory effects on cells of the immune system and may potentially affect RA disease activity and thereby RA-related fatigue. The purpose of this study was to explore associations between fatigue and vitamin D status in patients with RA.DesignHypothesis-generating cross-sectional study.SettingScheduled follow-up visits at a hospital-based general rheumatology clinic.ParticipantsPatients (n=169) with established RA.Primary outcome measures and anlysesFatigue, assessed by the Chalder fatigue questionnaire, and serum concentrations of 25-hydroxyvitamin D (25(OH)D), assessed by liquid chromatography–tandem mass spectrometry. Associations were analysed by correlation, and multivariate linear regression with adjustments for age, sex, body mass index, RA disease activity as measured by the Disease Activity Score 28-joint count C reactive protein (DAS28-CRP), psychological distress, pain and sleep. Fatigue was also compared across four groups based on the levels of serum 25(OH)D with cut points at 30, 50 and 75 nmol/L using one-way analysis of variance.ResultsTwo-thirds of the patients (116/169, 69%) were classified with low RA disease activity, that is, a DAS28-CRP score below 3.2. Their mean (SD) serum 25(OH)D concentration was 56.3 (21.2) nmol/L, with 77 (45.6%) having values below 50 nmol/L and 12 patients (7.1%) below 30 nmol/L. The correlation between fatigue and serum concentrations of 25(OH)D was weak and not statistically significant, r = −0.14 (95% CI: −0.29 to 0.03, p=0.08). In the multivariate model, fatigue was significantly associated with RA disease activity, psychological distress and pain, but not with serum 25(OH)D. Fatigue did not differ across groups with varying levels of serum 25(OH)D.ConclusionThis cross-sectional study found no evidence of association between vitamin D and fatigue in patients with RA.

Download Full-text

The Relationship of Cytokines IL-13 and IL-17 with Autoantibodies Profile in Early Rheumatoid Arthritis

Journal of Immunology Research ◽

10.1155/2016/3109135 ◽

2016 ◽

Vol 2016 ◽

pp. 1-10 ◽

Cited By ~ 12

Author(s):

Isabela Siloşi ◽

Mihail Virgil Boldeanu ◽

Manole Cojocaru ◽

Viorel Biciuşcă ◽

Vlad Pădureanu ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Disease Activity ◽

Early Rheumatoid Arthritis ◽

Disease Activity Score ◽

High Specificity ◽

Serum Levels ◽

Activity Score ◽

Serum Concentrations ◽

Serum Samples ◽

And Control

Aims.In the present study, we aimed to assess the concentrations of IL-13 and IL-17 in serum of patients with early rheumatoid arthritis (eRA), the investigation of correlation between the concentrations of these cytokines and disease activity score, and the concentration of some autoantibodies and the evaluation of the utility of IL-13 and -17 concentration measurements as markers of disease activity.Materials and Methods. Serum samples were collected from 30 patients and from 28 controls and analysed parameters.Results. The serum concentrations of IL-13, IL-17, anti-CCP, and IgM-RF were statistically significantly higher in patients with eRA, compared to the controls. IL-13 concentrations in the severe and moderate groups with eRA were statistically higher than in the mild and control groups. Also, in the case of IL-17, serum concentrations increased proportionally with the disease activity of eRA. We observe that concentrations of IL-13 and -17 did not correlate with autoantibodies. IL-17 concentration significantly positively correlated with CRP, while IL-13 concentration significantly negatively correlated with CRP. Disease activity score, DAS28, was strongly positively correlated with levels of ESR and weakly positively correlated with concentrations of anti-RA33 autoantibodies. IL-13 has a higher diagnostic utility than IL-17, CRP, ESR, IgM-RF, and anti-CCP as markers of disease activity.Conclusions. The presence of higher IL-13 and IL-17 serum levels in patients, compared with those of controls, confirms that these markers, found with high specificity, might be involved in the pathogenesis of eRA. IL-13 and IL-17 might be of better usefulness in the prediction of eRA activity status than IgM-RF and anti-CCP.

Download Full-text

AB0101 ASSOCIATION OF FETUIN-A SERUM LEVEL AND GLUCOCORTICOIDS INTAKE IN PATIENTS WITH RHEUMATOID ARTHRITIS

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2020-eular.1663 ◽

2020 ◽

Vol 79 (Suppl 1) ◽

pp. 1350.2-1350

Author(s):

E. Papichev ◽

В. Zavodovsky ◽

A. Yury ◽

S. L ◽

P. J

Keyword(s):

Rheumatoid Arthritis ◽

Serum Level ◽

Disease Activity ◽

Metabolic Diseases ◽

Glucocorticoid Therapy ◽

Serum Concentrations ◽

Coronary Artery Diseases ◽

Fetuin A ◽

The Mean ◽

Group Statistic

Background:Fetuin-A (FA) is a pluripotential glycoprotein, which plays an important role in bone turnover [1], inflammation, metabolic diseases [2] and etc. Several studies demonstrated association between FA serum level and rheumatoid arthritis (RA) severity and disease activity [3], however, there was made a suggestion that observed associations were due to glucocorticoids intake [4].Objectives:To study the association of serum FA levels, glucocorticoids intake and RA activity.Methods:81 patients with RA verified by ACR/EULAR 2010 criteria were enrolled in our study. 43 patients were under glucocorticoid therapy with mean cumulative dose 7899±9029,4 mg (hereinafter M±SD) and 38 patients were not. DAS28 index was calculated to determine RA activity. FA serum concentrations were measured by ELISA. Correlations between serum FA levels and RA activity were assessed in each group. Statistic analysis was performed using software package “Statistica 10.0”.Results:The mean level of serum FA was 760,72±112,56 µg/ml. There was a negative correlation between FA serum level and DAS28 index (r=-0,433; p<0,0001) when calculated among all patients. We observed positive correlation between FA serum level and cumulative dosage of glucocorticoids (r=0,297; p=0,008). At the same time FA serum level and DAS28 index were correlated negatively in patients who were under glucocorticoid therapy (r=-0,419; p<0,0001) and were not (r=-0,559; p=0,001).Conclusion:Serum FA level correlates with RA disease activity and glucocorticoids intake. However, the association between FA serum level and RA disease activity was independent of glucocorticoids intake in our study.References:[1]Akhverdyan Y., Zavodovsky B., Polyakova J., et al. Level of biochemical markers of bone metabolism in patients with osteoporosis in the presence on rheumatoid arthritis. Osteoporosis international 2019; 30(Suppl. 2): S:303.[2]Bilgir O, Kebapcilar L, Bilgir F, et al; Decreased serum fetuin-A levels are associated with coronary artery diseases. Intern Med 2010; 49(13): 1281-5.[3]Polyakova Y., Papichev E., Kvlividze T., et al. Tissue cytokines and their role in the pathogenesis of rheumatic diseases. Osteoporosis international 2019; 30 (Suppl. 2): S:387.[4]Tekeoglu I, Harman H, Sag S, et al. Levels of serum pantraxin 3, IL-6, fetuin A and insulin in patients with rheumatoid arthritis. Cytokine 2016; 83: 171-75.Disclosure of Interests:None declared

Download Full-text